| 15.705 -0.445 (-2.76%) | 07-02 15:58 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 26.6 | 1-year : | 32.11 |
| Resists | First : | 22.78 | Second : | 27.5 |
| Pivot price | 17.59 |
|||
| Supports | First : | 15.14 | Second : | 12.6 |
| MAs | MA(5) : | 16.28 |
MA(20) : | 18.55 |
| MA(100) : | 23.58 |
MA(250) : | 24.14 |
|
| MACD | MACD : | -2 |
Signal : | -1.8 |
| %K %D | K(14,3) : | 12.5 |
D(3) : | 15.2 |
| RSI | RSI(14): 30.8 |
|||
| 52-week | High : | 63 | Low : | 0.26 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ GLYC ] has closed above bottom band by 23.1%. Bollinger Bands are 31.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 17.5 - 17.67 | 17.67 - 17.77 |
| Low: | 15.19 - 15.39 | 15.39 - 15.51 |
| Close: | 15.47 - 15.8 | 15.8 - 16 |
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Thu, 05 Jun 2025
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals - Business Wire
Tue, 06 May 2025
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – GLYC, BRZH, PRA, FVNNU - Morningstar
Tue, 29 Apr 2025
GlycoMimetics Amends Merger Agreement With Crescent Biopharma - Investing.com
Fri, 14 Feb 2025
GlycoMimetics adjusts merger terms with Crescent Biopharma - Investing.com
Thu, 13 Feb 2025
GLYCOMIMETICS INC SEC 10-K Report - TradingView
Tue, 12 Nov 2024
Crescent Biopharma to Showcase Cancer Drug Pipeline at Jefferies Healthcare Conference - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 65 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 2.6 (%) |
| Held by Institutions | 47.7 (%) |
| Shares Short | 17 (K) |
| Shares Short P.Month | 18 (K) |
| EPS | -46 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.23 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -74 % |
| Return on Equity (ttm) | -182.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.37 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -11 (M) |
| PE Ratio | -0.35 |
| PEG Ratio | 0 |
| Price to Book value | 3 |
| Price to Sales | 0 |
| Price to Cash Flow | -39.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|